Jefferies Boosts Eli Lilly Price Target to $1,700 as Stock Nears 52-Week High
By TrendSpider Editor
Jefferies (Akash Tewari) reaffirmed its Buy rating on Eli Lilly on November 10, 2026, while raising the price target to $1,700 from a prior target of $1,610. This is the sole analyst action in today's data. The consensus average price target stands at $1,700, aligning directly with Jefferies' update
Jefferies Boosts Eli Lilly Price Target to $1,700 as Stock Nears 52-Week High
Jefferies analyst Akash Tewari reaffirmed a Buy rating on Eli Lilly and Company while raising his price target from $1,610 to $1,700, signaling continued conviction in the pharma giant's growth trajectory. LLY shares are trading at $1,432.91, up 1.47% on the session, and sit comfortably near the top of their 52-week range of $850.51 to $1,453. The updated price target implies meaningful additional upside from current levels, reinforcing the bullish case for one of the most closely watched names in large-cap pharmaceuticals.Key Drivers of the LLY Stock Move
- Main Catalyst: Jefferies analyst Akash Tewari confirmed a Buy rating on LLY and raised the price target to $1,700 from a prior target of $1,610, representing a $90 increase in the firm's stated upside objective.
- Bull Case: The new $1,700 price target sits well above the current price of $1,432.91, offering approximately 18.6% implied upside based on Jefferies' revised estimate. With shares already up 1.47% on the session and trading near the 52-week high of $1,453, the confirmation from a major sell-side firm adds institutional credibility to the near-term momentum.
- Bear Case: LLY is approaching a critical technical ceiling with the 52-week high at $1,453 just above current trading levels. A failure to break through that resistance could limit near-term gains regardless of analyst optimism, and any broad market or sector-level headwinds could weigh on a stock already priced for strong execution.
LLY Analyst Ratings and Price Targets
Jefferies (Akash Tewari) reaffirmed its Buy rating on Eli Lilly on November 10, 2026, while raising the price target to $1,700 from a prior target of $1,610. This is the sole analyst action in today's data. The consensus average price target stands at $1,700, aligning directly with Jefferies' updated figure and reflecting strong sell-side confidence in the stock's long-term valuation relative to its current price of $1,432.91.
LLY Seasonality
Historically, large-cap pharmaceutical stocks tend to see increased institutional attention in November as portfolio managers position ahead of year-end, which can amplify the effect of bullish analyst actions during this period. With LLY near multi-year highs in mid-November, seasonal tailwinds may offer an additional supporting layer to the current technical and fundamental setup.
LLY Relative Performance
LLY is trading at $1,432.91, up 1.47% on the session, and is positioned near the upper end of its 52-week range spanning $850.51 to $1,453. The stock has recovered substantially from its 52-week low, more than doubling from that level, underscoring strong relative strength compared to the broader healthcare sector. The stock's proximity to its 52-week high of $1,453 suggests LLY has outperformed many of its large-cap pharma peers over the trailing year, maintaining a leadership position within the sector.
More on LLY
- Eli Lilly Hovers Just Below All-Time High as Stock Trades Near $1,444
- Eli Lilly Surges Toward 52-Week High as LLY Stock Approaches $1,460 Resistance
- Eli Lilly Holds Near All-Time Highs as Stock Dips Slightly to $1,429
- Eli Lilly Hovers Just Below All-Time High as Stock Climbs Toward $1,453 Resistance
- Eli Lilly Sees $2M Bearish Put Contract as Stock Trades Near 52-Week Lows
Latest Market News
- Palo Alto Networks Drops 7.94% Despite 20 Analyst Confirmations and $432 Average Price Target
- Meta Platforms Drops Nearly 6% as Shares Slide Toward 52-Week Low Territory
- Oracle Stock Craters 6.4%, Breaking Below Its 52-Week Low to $103.44
- QUALCOMM Shares Plunge 7.41% to $150.01, Nearing 52-Week Lows
- CrowdStrike Shares Crater 15% on Friday, Erasing Months of Gains in a Single Session
- Snowflake Shares Tumble 5.13% as Stock Retreats Sharply from Recent Highs